Physician profile
Efstratios Koutroumpakis
NPI 1619361003
$2,890.60
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $384 · 2021: $1,094 · 2022: $374 · 2023: $533 · 2024: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $977.72 | 2020-2023 | Amplatzer Amulet, Cardiomems |
| Impulse Dynamics (USA) INC. | $709.17 | 2022-2024 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $448.19 | 2020-2023 | Lifevest |
| W. L. Gore & Associates, INC. | $191.69 | 2024 | Gore Cardioform Septal Occluder |
| Astrazeneca Pharmaceuticals LP | $155.25 | 2020-2023 | Farxiga |
| Astellas Pharma US INC | $145.16 | 2020-2021 | |
| Tersera Therapeutics LLC | $109.31 | 2023 | Xermelo |
| Medtronic, INC. | $87.03 | 2021 | |
| Pfizer INC. | $31.83 | 2020-2021 | |
| Chiesi USA, INC. | $18.22 | 2020 | |
| Lilly USA, LLC | $17.03 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efstratios Koutroumpakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.